ARTICLE
21 April 2015

Dutch Court Denies Shareholder Vote On Fugro Poison Pill

DB
De Brauw Blackstone Westbroek N.V.

Contributor

De Brauw Blackstone Westbroek is a leading international law firm, trusted by clients for over 150 years due to its deep engagement with their businesses and a clear understanding of their ambitions. While rooted in Dutch society, the firm offers global coverage through its network of top-tier law firms, ensuring seamless, tailored legal solutions. De Brauw’s independence enables it to choose the best partners while remaining a trusted, strategic advisor to clients worldwide.

The firm emphasizes long-term investment in both its client relationships and its people. De Brauw’s legal training institutes, De Brauwerij and The Brewery, cultivate diverse talent, preparing the next generation of top-tier lawyers through rigorous training and personal development. Senior leadership traditionally rises from within, maintaining the firm’s high standards and collaborative culture.

This recommendation to the board was regarded by the court as a wish by Boskalis to dismantle the poison pill.
Netherlands Corporate/Commercial Law

The district court in The Hague will not order Fugro to include a vote on one of its poison pill defences on the annual shareholder meeting agenda. This is a matter of strategy reserved for the board, according to the court. The request for a court order was filed by Boskalis, which had at that point built up a 20% stake in Fugro. Boskalis wanted Fugro to let its shareholders vote at the AGM of April 30 on a recommendation to the board to do everything possible to end the anti-takeover measure.

This recommendation to the board was regarded by the court as a wish by Boskalis to dismantle the poison pill. Accordingly, it was a strategic matter for the board to decide on. Fugro's proposal to discuss the anti-takeover measure at its annual meeting was in line with the rationale behind the right of shareholders to put items on the agenda, namely to enhance the dialogue between shareholders and the board. Following the court's ruling, Boskalis has withdrawn the proposed agenda item.

For the full text of the ruling, please click here (Dutch only).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More